Trial Profile

Phase I Study of the Combination of Crizotinib and Dasatinib in Pediatric Research Participants With Diffuse Pontine Glioma and High-Grade Glioma

Status: Completed

Phase of Trial: Phase I

Latest Information Update: 05 Jan 2022

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Crizotinib (Primary) ; Dasatinib (Primary)
Indications Diffuse intrinsic pontine glioma; Glioma
Focus Adverse reactions

Most Recent Events

01 Dec 2021 Results of population pharmacokinetic analysis published in the Cancer Chemotherapy and Pharmacology
21 May 2021 Results (n=34) of a Population PK analysis presented at the 112th Annual Meeting of the American Association for Cancer Research
20 Mar 2019 Status changed from active, no longer recruiting to completed.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com